Provided by Tiger Trade Technology Pte. Ltd.

Pasithea Therapeutics Corp.

1.06
+0.5724117.39%
Post-market: 0.9296-0.1304-12.30%19:59 EST
Volume:159.52M
Turnover:165.25M
Market Cap:7.89M
PE:-0.33
High:1.34
Open:0.5100
Low:0.5069
Close:0.4876
52wk High:3.85
52wk Low:0.2810
Shares:7.44M
Float Shares:7.33M
Volume Ratio:9.36
T/O Rate:2175.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2501
EPS(LYR):-12.6857
ROE:-89.90%
ROA:-53.70%
PB:0.65
PE(LYR):-0.08

Loading ...

Pasithea announces activation of trial site at UAB for study of PAS-004

TIPRANKS
·
Nov 04

Pasithea Therapeutics Raises Executive Salaries and Grants New Stock Options

Reuters
·
Oct 28

Pasithea Therapeutics’ Promising Phase 1 Study on PAS-004 for Advanced Solid Tumors

TIPRANKS
·
Oct 28

Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

GlobeNewswire
·
Sep 16

BRIEF-Pasithea Therapeutics Announces Enrollment Of Cohort 2 Following Positive Safety Review Committee (SRC) Recommendation

Reuters
·
Sep 08

Pasithea Therapeutics Announces Enrollment of Cohort 2 Following Positive Safety Review Committee (Src) Recommendation for Its Ongoing Phase 1/1B Clinical Trial of Pas-004 in Adult Nf1 Patients

THOMSON REUTERS
·
Sep 08

Pasithea Therapeutics Corp - Interim Data From First Two Cohorts Expected Q1 2026

THOMSON REUTERS
·
Sep 08

Pasithea Therapeutics Corporation Held Annual Stockholders Meeting

Reuters
·
Sep 04

Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire
·
Aug 29

BRIEF-Pasithea Completes Enrollment, Dosing of First Cohort in PAS-004 Phase 1/1B NF1 Trial

Reuters
·
Jul 31

Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort From Its Phase 1/1B Clinical Trial of Pas-004 in Adult Nf1 Patients

THOMSON REUTERS
·
Jul 31

Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients

GlobeNewswire
·
Jul 31

Pasithea Therapeutics Receives Nasdaq Notice for Non-Compliance with $1 Minimum Bid Price Rule

Reuters
·
Jun 28

Pasithea Therapeutics Increases Offering Price to $4.23M, Registers Additional $2.15M in Common Stock Sales

Reuters
·
Jun 21